Ergoflo N Tablet is a combination medication containing Acebrophylline 100 mg and Acetylcysteine 600 mg, primarily indicated for the management of respiratory conditions characterized by bronchial obstruction and excessive mucus production. Acebrophylline, a xanthine derivative, exhibits bronchodilator and mucosecretolytic properties, facilitating the relaxation of bronchial smooth muscles and enhancing mucociliary clearance. Acetylcysteine, a mucolytic agent, acts by disrupting disulfide bonds in mucus glycoproteins, thereby reducing sputum viscosity and promoting expectoration. This dual-action formulation is effective in treating chronic obstructive pulmonary disease (COPD), bronchitis, asthma, and other respiratory tract disorders associated with thick, tenacious mucus. Ergoflo N Tablet improves airway patency, alleviates cough, and enhances respiratory function, contributing to symptomatic relief and improved quality of life. The combination therapy is generally well tolerated; however, it should be used with caution in patients with hypersensitivity to either component, peptic ulcer disease, or severe hepatic or renal impairment. Common adverse effects may include gastrointestinal disturbances, headache, and hypersensitivity reactions. Ergoflo N Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on clinical response and patient tolerance. Regular monitoring is advised during prolonged therapy to ensure safety and efficacy.